|Welcome to JEIL.
||March 7th, 1959
||KOSPI, IPO in 1988
|Employees (end of 2018)
|Annual Sales (2018)
||KRW 680 billion (USD 580 million)
||Head Office in Seoul, Korea
Factory and R&D Center in Yongin-si, Gyeonggi-do, Korea
Pharmaceutical Technology Research Institute at Yongin Technovalley,
Yongin-si, Gyeonggi-do, Korea
Founded in 1959, Jeil has developed and supplied superior pharmaceutical products to promote the happiness and health of mankind and has contributed to the growth and development of the pharmaceutical industry in Korea.
Jeil has been listed on KOSPI since 1988. As of 2018, Jeil is constituted of 1143 employees and has sales amount reaching above 680 billion Korean wons.
The Central R&D Center established in 1980 forms the core of the R&D activities of Jeil. Currently, as of 2018, the new drug development laboratory, the pharmacology & toxicology laboratory, the organic synthesis laboratory, the formulation laboratory, and the analysis laboratory are actively engaged in conducting research into the complete manufacture and ingredients of innovative new drugs, incrementally modified drugs, and generic drugs.
Jeil’s factory established in 1986 and located in Yongin-si, Korea was accredited as fulfilling KGMP in 1987, and produces tablets, capsules, injections, finished pharmaceutical products including patches, and Active Pharmaceutical Ingredients(APIs) such as anti-biotic ingredients, etc. The construction of new factory with the most up-to-dated facilities, which complies with EU-GMP and US-GMP, has been completed in 2016.
In May of 2018, Jeil established Pharmaceutical Technology Research Institute, a formulation and analysis lab, at Yongin Technovalley in Yongin-si, Korea to further improve and invest in research and development of Incrementally Modified Drug (IMD) and generic products.
Jeil, equipped with global-class research centers and production facilities, has been recognized for its outstanding value on the world market as well. In the ingredients sector, Jeil exports synthetic ingredients such as Cefditoren Pivoxil, Epinastine HCl, etc. to Japan and China, while also supplies finished products such as Kefentech Plaster (Ketoprofen), Cilapenem Injection (Imipenem / Cilastatin Sodium), etc. to more than 40 countries in ASEAN, Central and South America, Africa, etc.
Within the South Korean market, Jeil operates a well-trained MR organization to cover the nation-wide market based on science and evidence, and thereby has become a supplier of over 70 prescription drugs and over 30 over-the-counter drugs.
Beginning in the period between 1970 and 1980, Jeil has engaged in technological partnerships (licensing) with global pharmaceutical companies to provide the domestic market with outstanding new drugs. It has also been the first Korean company to engage in co-promotion successfully with the globally renowned company Pfizer, executing a win-win strategy with our overseas collaborative partners and thus winning recognition as an advanced pharmaceutical company adapted to internationalized business practices.
We thank all of the visitors to our Jeil’s homepage for their interest and encourage you to contact us for further business progress.